Freeline Therapeutics Holdings Future Growth
Future criteria checks 2/6
Freeline Therapeutics Holdings is forecast to grow earnings and revenue by 22.5% and 60.3% per annum respectively while EPS is expected to grow by 69.9% per annum.
Key information
22.5%
Earnings growth rate
69.9%
EPS growth rate
| Biotechs earnings growth | 31.1% |
| Revenue growth rate | 60.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Aug 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 26 | -46 | -43 | -28 | 3 |
| 12/31/2024 | N/A | -76 | -72 | -69 | 4 |
| 12/31/2023 | 5 | -55 | -53 | -62 | 4 |
| 3/31/2023 | N/A | -61 | -77 | -70 | N/A |
| 12/31/2022 | N/A | -89 | -85 | -78 | N/A |
| 9/30/2022 | N/A | -101 | -79 | -76 | N/A |
| 6/30/2022 | N/A | -117 | -86 | -83 | N/A |
| 3/31/2022 | N/A | -132 | -102 | -100 | N/A |
| 12/31/2021 | N/A | -140 | -112 | -108 | N/A |
| 9/30/2021 | N/A | -144 | -129 | -124 | N/A |
| 6/30/2021 | N/A | -138 | -136 | -132 | N/A |
| 3/31/2021 | N/A | -115 | -115 | -111 | N/A |
| 12/31/2020 | N/A | -96 | -97 | -95 | N/A |
| 9/30/2020 | N/A | -73 | -73 | -72 | N/A |
| 6/30/2020 | N/A | -63 | -53 | -51 | N/A |
| 3/31/2020 | N/A | -58 | -57 | -54 | N/A |
| 12/31/2019 | N/A | -54 | -55 | -52 | N/A |
| 12/31/2018 | N/A | -33 | -30 | -26 | N/A |
| 9/30/2017 | N/A | -17 | -20 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 78F0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 78F0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 78F0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 78F0's revenue (60.3% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 78F0's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 78F0's Return on Equity is forecast to be high in 3 years time